Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
56.39 ^USD	-3.80%		+2.17%	+41.83%

Mar. 19	Morphic Holding Names Simon Cooper as Chief Medical Officer	MT
Mar. 15	Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug	MT

Keros Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 06, 2023 at 08:06 am EST

Keros Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.008 million. Net loss was USD 39.44 million compared to USD 23.51 million a year ago. Basic loss per share from continuing operations was USD 1.33 compared to USD 0.92 a year ago.
For the nine months, revenue was USD 0.008 million. Net loss was USD 112.75 million compared to USD 74.96 million a year ago. Basic loss per share from continuing operations was USD 3.86 compared to USD 3.05 a year ago.

Latest news about Keros Therapeutics, Inc.

Morphic Holding Names Simon Cooper as Chief Medical Officer	Mar. 19	MT
Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug	Mar. 15	MT
Keros Therapeutics Gets FDA Fast Track Designation for Anemia Drug	Mar. 14	MT
Keros Gets FDA Fast-Track Designation for Lead Drug KER-050	Mar. 14	DJ
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	Mar. 14	CI
Keros Therapeutics, Inc. Announces Resignation of Simon Cooper, M.B.B.S., as Chief Medical Officer, Effective March 12, 2024	Mar. 05	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q4 Revenue $143,000	Feb. 28	MT
Keros Therapeutics Closes $151.3 Million Stock Offering	Jan. 09	MT
Keros Therapeutics Prices Stock Offering at $40 a Share	Jan. 04	MT
Keros Therapeutics Proposes $120 Million Common Stock Offering	Jan. 03	MT
Keros Therapeutics Starts Phase 1 Clinical Trial of Potential Obesity Treatment	Jan. 03	MT
Keros Therapeutics, Inc. to Develop KER-065 for the Treatment of Obesity	Jan. 03	CI
Keros Therapeutics Shares Fall After Reporting Additional Data From Trial of KER-050 With Potential for Treating Cytopenia	Dec. 11	MT
Sector Update: Health Care Stocks Advance Premarket Monday	Dec. 11	MT
Keros Therapeutics Says Additional Data From Trial of KER-050 Shows Potential for Treating Cytopenia	Dec. 11	MT
Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition	Dec. 11	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q3 Revenue $8,000	Nov. 06	MT
Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society	23-10-04	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Wedbush Starts Keros Therapeutics at Outperform With $86 Price Target	23-07-31	MT
BofA Securities Initiates Keros Therapeutics With Buy Rating, $65 Price Target	23-07-26	MT
BofA Securities Starts Keros Therapeutics at Buy With $65 Price Target	23-07-26	MT

Chart Keros Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Keros Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

56.39 USD

Average target price

88.11 USD

Spread / Average Target

+56.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KEROS THERAPEUTICS, INC.	+41.83%	2.03B
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.21%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs